Hillsdale Investment Management’s Pacira BioSciences PCRX Stock Holding History

Hillsdale Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.49M	Buy	331,300 +23,100	+7%	+$513K	0.2%	105
2025 Q4	$7.98M	Buy	+308,200	New	+$7.33M	0.22%	90
2024 Q4	–	Sell	-229,200	Closed	-$3.45M	–	655
2024 Q3	$3.45M	Buy	229,200 +134,100	+141%	+$2.29M	0.27%	153
2024 Q2	$2.72M	Sell	95,100 -50,300	-35%	-$1.43M	0.21%	168
2024 Q1	$4.25M	Buy	145,400 +11,400	+9%	+$350K	0.34%	105
2023 Q4	$4.52M	Buy	+134,000	New	+$3.92M	0.37%	84
2019 Q4	–	Sell	-18,200	Closed	-$693K	–	644
2019 Q3	$693K	Hold	18,200	–	–	0.06%	280
2019 Q2	$792K	Buy	18,200 +3,400	+23%	+$144K	0.08%	238
2019 Q1	$563K	Buy	14,800 +4,200	+40%	+$164K	0.05%	269
2018 Q4	$456K	Buy	+10,600	New	+$495K	0.05%	256

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hillsdale Investment Management's PCRX Position: Q1 2026 in Review

Hillsdale Investment Management increased its Pacira BioSciences (PCRX) stake by 7.5% in Q1 2026, buying an estimated $513K and bringing the position to 331,300 shares worth $7.49M. The position accounts for 0.2% of the portfolio, ranked #105.

Hillsdale Investment Management first reported a position in PCRX in Q4 2018 and has held it in 10 quarters since. The position peaked at $7.98M in Q4 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Hillsdale Investment Management held 331,300 shares of Pacira BioSciences worth $7.49M as of Q1 2026.
Hillsdale Investment Management bought 23,100 Pacira BioSciences shares in Q1 2026, an estimated $513K.
Pacira BioSciences made up 0.2% of Hillsdale Investment Management's portfolio in Q1 2026, its #105 holding.
Hillsdale Investment Management first reported a position in Pacira BioSciences in Q4 2018 and has held it in 10 quarters since.
Hillsdale Investment Management's Pacira BioSciences position peaked at $7.98M in Q4 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.